In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $46.75 down -26.56% from its previous closing price of $63.66. In other words, the price has decreased by -$26.56 from its previous closing price. On the day, 14.9 million shares were traded.
Ratios:
For a deeper understanding of Sarepta Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.87.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on April 11, 2025, initiated with a Overweight rating and assigned the stock a target price of $115.
On April 02, 2025, H.C. Wainwright Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $75.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on March 31, 2025, whereas the target price for the stock was revised from $161 to $87.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
As of this moment, Sarepta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.61, and their Forward P/E ratio for the next fiscal year is 3.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.42 while its Price-to-Book (P/B) ratio in mrq is 2.97.
Stock Price History:
Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $48.01. The 50-Day Moving Average of the stock is -36.85%, while the 200-Day Moving Average is calculated to be -58.40%.
Shares Statistics:
A total of 96.90M shares are outstanding, with a floating share count of 92.29M. Insiders hold about 6.07% of the company’s shares, while institutions hold 87.94% stake in the company.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $2.65, with high estimates of $3.47 and low estimates of $2.03.
Analysts are recommending an EPS of between $12.99 and $3.22 for the fiscal current year, implying an average EPS of $7.6. EPS for the following year is $13.83, with 13.0 analysts recommending between $17.52 and $8.97.
Revenue Estimates
A total of 17 analysts believe the company’s revenue will be $739.59M this quarter.It ranges from a high estimate of $938.76M to a low estimate of $631.5M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $362.93MFor the next quarter, 17 analysts are estimating revenue of $782.63M. There is a high estimate of $880M for the next quarter, whereas the lowest estimate is $704.78M.
A total of 21 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $3.45B, while the lowest revenue estimate was $2.7B, resulting in an average revenue estimate of $3.05B. In the same quarter a year ago, actual revenue was $1.9BBased on 19 analysts’ estimates, the company’s revenue will be $3.75B in the next fiscal year. The high estimate is $4.4B and the low estimate is $3.16B.
